[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616783":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":34,"responsibleParty":80,"collaborators":32,"id":82,"slug":32,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":32,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":32,"enrollmentInfo":90,"targetDuration":32,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":32,"overallStatus":37,"whyStopped":32,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Xian-Janssen Pharmaceutical Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Guselkumab Treatment","EXPERIMENTAL","Participants will receive Guselkumab intravenously (IV) every 4 weeks during the induction phase, followed by subcutaneous (SC) administration of Guselkumab every 4 weeks from Week 12 through Week 44 as maintenance therapy.",[13],"Drug: Guselkumab (GUS)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Guselkumab (GUS)","Guselkumab will be administered intravenously or by subcutaneous injection.",[9],[21],"TREMFYA",[23],{"name":24,"affiliation":25,"role":26},"Xi'an Janssen Pharmaceutical Clinical Trial","Xi'an Janssen Pharmaceutical","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Study Contact","CONTACT","844-434-4210",null,"Participate-In-This-Study1@its.jnj.com",[35,47,53,62,71],{"facility":36,"status":37,"city":38,"state":32,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":32},"The First Affiliated Hospital Sun Yat sen University","RECRUITING","Guangzhou","510060","China",{"type":42,"coordinates":43},"Point",[44,45],113.25,23.11667,{"lat":45,"lon":44},{"facility":48,"status":37,"city":38,"state":32,"zip":49,"country":40,"cosmosGeoPoint":50,"geoPoint":52,"contacts":32},"The Sixth Affiliated Hospital Sun Yat sen University","510655",{"type":42,"coordinates":51},[44,45],{"lat":45,"lon":44},{"facility":54,"status":37,"city":55,"state":32,"zip":56,"country":40,"cosmosGeoPoint":57,"geoPoint":61,"contacts":32},"Sir Run Run Shaw Hospital Zhejiang University School of Medicine","Hangzhou","310018",{"type":42,"coordinates":58},[59,60],120.16142,30.29365,{"lat":60,"lon":59},{"facility":63,"status":37,"city":64,"state":32,"zip":65,"country":40,"cosmosGeoPoint":66,"geoPoint":70,"contacts":32},"The First Affiliated Hospital of Anhui Medical University","Hefei","230022",{"type":42,"coordinates":67},[68,69],117.28083,31.86389,{"lat":69,"lon":68},{"facility":72,"status":37,"city":73,"state":32,"zip":74,"country":40,"cosmosGeoPoint":75,"geoPoint":79,"contacts":32},"Ruijin Hospital","Shanghai","200031",{"type":42,"coordinates":76},[77,78],121.45806,31.22222,{"lat":78,"lon":77},{"type":81,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100616783",false,"NCT07310095","A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)","Efficacy of Guselkumab in Chinese Participants With Crohn's Disease Following Loss of Response to Ustekinumab","Inclusion Criteria:\n\n* Has a confirmed diagnosis of Crohn's disease (CD)\n* Diagnosed with active CD, as defined by baseline Crohn's Disease Activity Index (CDAI) score greater than or equal to (\\>=) 220 and either mean daily stool frequency (SF) count \\>= 4 or mean daily abdominal pain (AP) score \\>=2\n* Participants had received at least two doses of ustekinumab (UST) (induction of 6 milligram \\[mg\\]\u002Fkilogram \\[kg\\] intravenous \\[IV\\] followed by 90 mg subcutaneous \\[SC\\] at week 8) as the instruction manual\n* Initially responded to UST induction therapy and then lose response to UST\n* During the screening period, participants are receiving UST treatment as the first line biologic or second line biologic\n\nExclusion Criteria:\n\n* Have responded well to treatment with UST in a dosing regime that is not in line with to the approved recommended dosing (for example, multiple intravenous induction) experienced optimized treatment with UST(not as instruction manual)\n* Participants with CD requiring urgent surgical or endoscopic intervention, or requiring elective surgery within 2 months\n* Is currently enrolled in an interventional clinical study\n* Complications of CD, such as symptomatic strictures or stenoses, short gut syndrome\n* Have a current or be suspected to have an abscess","ALL","18 Years",{"count":91,"type":92},78,"ESTIMATED","INTERVENTIONAL",[95],"PHASE4","The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.",[98],"Crohn Disease","2026-06-04",{"date":101,"type":102},"2026-06-05","ACTUAL",{"date":104,"type":102},"2025-12-30",{"date":106,"type":92},"2027-11-15",{"name":5,"class":6},5]